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Abstract
We have shown that lithium treatment improves motor coordination in a spinocerebellar ataxia type 1 (SCA1) disease
mouse model (Sca1154Q/+). To learn more about disease pathogenesis and molecular contributions to the neuroprotective
effects of lithium, we investigated metabolomic profiles of cerebellar tissue and plasma from SCA1-model treated and
untreated mice. Metabolomic analyses of wild-type and Sca1154Q/+ mice, with and without lithium treatment, were
performed using gas chromatography time-of-flight mass spectrometry and BinBase mass spectral annotations. We
detected 416 metabolites, of which 130 were identified. We observed specific metabolic perturbations in Sca1154Q/+ mice
and major effects of lithium on metabolism, centrally and peripherally. Compared to wild-type, Sca1154Q/+ cerebella
metabolic profile revealed changes in glucose, lipids, and metabolites of the tricarboxylic acid cycle and purines. Fewer
metabolic differences were noted in Sca1154Q/+ mouse plasma versus wild-type. In both genotypes, the major lithium
responses in cerebellum involved energy metabolism, purines, unsaturated free fatty acids, and aromatic and sulphur-
containing amino acids. The largest metabolic difference with lithium was a 10-fold increase in ascorbate levels in wild-type
cerebella (p,0.002), with lower threonate levels, a major ascorbate catabolite. In contrast, Sca1154Q/+ mice that received
lithium showed no elevated cerebellar ascorbate levels. Our data emphasize that lithium regulates a variety of metabolic
pathways, including purine, oxidative stress and energy production pathways. The purine metabolite level, reduced in the
Sca1154Q/+ mice and restored upon lithium treatment, might relate to lithium neuroprotective properties.
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Introduction
Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant
neurodegenerative disease that is caused by the expansion of a
translated CAG repeat in ATAXIN1 (ATXN1). SCA1 is character-
ized by progressive loss of balance and coordination, mild
cognitive impairments, speaking and swallowing difficulties, and
eventually respiratory failure leading to premature death [1]. The
toxic effects of the glutamine-expanded protein result in variable
degrees of neurodegeneration, predominantly in the cerebellum,
brainstem and spinocerebellar tracts [2]. A knock-in mouse model
of SCA1 (Sca1154Q/+) recapitulates many aspects of the human
disease [3], enabling us to study SCA1 pathophysiology and test
therapeutic candidates. Molecular mechanisms that underlie the
pathophysiology of SCA1 are slowly becoming understood [4].
The dysregulation of several neuronal genes that has been
observed in the tissue of humans with SCA1 has also been found
in the Purkinje cells of SCA1 transgenic mice, even at the pre-
symptomatic stage [4]. In light of this notion, Watase et al. [5]
treated Sca1154Q/+ mice with lithium—which exerts neuroprotec-
tive effects possibly by affecting gene transcription—and demon-
strated that lithium rescues several SCA1 phenotypes in this
model.
Lithium has been the standard pharmacological treatment for
bipolar disorder for over fifty years. During the past two decades,
attention has been drawn to the neuroprotective properties of
lithium against diverse insults, including glutamate-induced
excitotoxicity and endoplasmic reticulum stress [6]. Multiple
molecular pathways such as phosphoinositides [7,8], protein
kinase C signaling pathway [9] and glycogen synthase kinase 3
activity could explain some of the neuroprotective properties of
lithium [10–13].
It is unclear how lithium improves the SCA1 disease model and
what metabolic changes might be modified. There is no biological
marker for following the SCA1 disease course or for measuring the
effects of lithium or any other therapy on patients under the
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treatment. To seek potential markers and a deeper understanding
of the disease pathogenesis and response to lithium, we applied
techniques from the rapidly-evolving field of metabolomics, which
enables the identification and quantification of hundreds of small
molecules in cells, tissues and body fluids. The metabolic profile of
an individual captures a metabolic state at a certain point in time
and is regulated by net interactions between gene products and
environmental influences [14]. Metabolic profiles could provide
valuable insights into disease mechanisms, and can lead to the
development of diagnostic and intervention assessment markers
[15–17]. Metabolic signatures have been found for a variety of
diseases, including neurodegenerative disorders [15,17], substance
abuse [18,19] and drugs used for the treatment of these disorders
[15,20].
Differences between individuals make it difficult to find a
homogeneous group of human participants for studying the final
metabolic output of the treatment and disease. Having an
authentic mouse model of SCA1 disease [3] together with a
carefully controlled lithium treatment provides the opportunity to
discover biochemical changes in SCA1 disease and lithium
treatment which can then be specifically explored in human
patients.
In this study, we used a non-targeted mass-spectrometry-based
metabolomics platform to map biochemical changes in the
cerebellum and plasma of Sca1154Q/+ mice with and without
lithium treatment compared to their wild-type littermates.
Materials and Methods
Mouse maintenance, diet and dissection
Mouse generation and treatment were performed as described
in Watase et al. [5]. In brief, Sca1154Q/+ mice and their wild-type
littermates were obtained from crossings between male Sca1154Q/+
mice and wild-type female mice. All mice were on pure C57Bl/6
background. The mice were randomly assigned to two groups at
the time of weaning (presymptomatic), when treatment was
initiated. Animals were housed in groups of 3 to 5 per cage in a
12 hour light/dark cycle, with free access to food and water. For
10–12 weeks, each group was fed either chow containing 0.2%
lithium carbonate or control Purina rodent chow (Harlan Teklad,
http://www.teklad.com). At 13–15 weeks of age, the animals were
anesthetized. Their blood was obtained via cardiac puncture and
collected in EDTA-containing separator tubes. The plasma was
separated from blood cells, aliquoted and frozen. The cerebella
were dissected on a chilled plate and frozen in liquid nitrogen. All
samples were kept at 280uC for later analysis. Mouse experiments
followed protocols approved by the Baylor College of Medicine
Institutional Animal Care and Use Committee and the Institu-
tional Animal Care and Use Committee of Tokyo Medical and
Dental University.
Blood sample preparation analysis
Plasma samples (30 ml) were thawed on ice and vortexed for
10 seconds. Aliquots (15 ml) were extracted with 1 ml of a carefully
degassed solvent mixture of 3:3:2 (v/v/v) acetonitrile:isopropanol:-
water at 220uC to perform protein precipitation and metabolite
extraction. The plasma/solvent mixture was vortexed for 10 sec-
onds and shaken for 4–6 minutes at 4uC. A subsequent
centrifugation step removed insoluble proteins and cell membrane
components. The supernatant was dried down using a speed
vacuum concentration system (Labconco Centrivap cold trap). To
remove most of the membrane lipids and triglycerides, which may
interfere with the analysis of amino acids in gas chromatograph
mass spectroscopy, 500 ml of a degassed mixture of 1:1 (v/v)
acetonitrile/water was added and the sample underwent vortexing
for 10 seconds, ultrasonication for 20 seconds and centrifugation
at 13,0006 g for 2 minutes. Afterward, 450 ml were decanted,
which was dried down by speed vac for derivatization and analysis.
A mixture of internal retention index markers was prepared using
fatty acid methyl esters of C8, C9, C10, C12, C14, C16, C18,
C20, C22, C24, C26, C28 and C30 linear chain length, and was
dissolved in chloroform at a concentration of 0.8 mg/ml (C8–C16)
and 0.4 mg/ml (C18–C30). One ml of this retention index mixture
was added to the dried extracts. Ten ml of a solution of 20 mg/ml
of 98% pure methoxyamine hydrochloride (Sigma, St. Louis MO)
in pyridine (silylation grade, Pierce, Rockford IL) was added and
shaken at 30uC for 90 minutes to protect aldehyde and ketone
groups. Ninety ml of N-methy-N-(trimethylsilyl) trifluoroacetamide
(1 ml bottles, Sigma-Aldrich) was added for trimethylsilylation of
acidic protons and shaken at 37uC for 30 minutes. The reaction
mixture was transferred to a 2 ml clear glass autosampler vial with
microinsert (Agilent, Santa Clara CA) and closed using an 11 mm
T/S/T crimp cap (MicroLiter, Suwanee GA).
Gas Chromatograph Time-of-Flight mass spectrometry
A Gerstel MPS2 automatic liner exchange system was used to
inject 0.5 ml of sample at 50uC (ramped to 250uC) in splitless mode
with 25 seconds splitless time. An Agilent 6890 gas chromatograph
(Santa Clara CA) was used with a 30 m long, 0.25 mm i.d.
Rtx5Sil-MS column with 0.25 mm 5% diphenyl film and an
additional 10 m integrated guard column (Restek, Bellefonte PA).
Chromatography was performed at a constant flow of 1 ml/
minute, ramping the oven temperature from 50uC to 330uC with
22 minutes total run time. Mass spectrometry was performed
using a Leco Pegasus IV time-of-flight mass spectrometer with a
280uC transfer line temperature, electron ionization at270 V and
an ion source temperature of 250uC. Mass spectra were acquired
from m/z 85–500 at 17 spectra s-1 and 1850 V detector voltage.
Result files were exported to the Fiehnlab servers and further
processed by the in-house metabolomics BinBase database. All
database entries in BinBase were matched against the Fiehn mass
spectral library of 1,200 authentic metabolite spectra using
retention index and mass spectrum information or the National
Institute of Standards and Technology, version 5 commercial
library. Identified metabolites were reported if they were present in
at least 50% of the samples per study design group (as defined in
the SetupX database). Quantitative data were normalized to the
sum intensities of all known metabolites and used for statistical
investigation.
Statistical analysis
Multivariate statistics and one-way analysis of variance
(ANOVA) models were calculated using Statistica data miner
V8 (Statsoft, Tulsa OK, USA). The ANOVA results were used for
box-whisker plots and tables, and were subsequently converted
into a Cytoscape node attribute file which was utilized to visualize
the differential statistics on network graphs. Multivariate partial
least square analysis was performed using the non-linear iterative
partial lease squares algorithm using unit standard deviation
scaling, 50 iterations with 0.0001 as convergence criterion and 7-
fold cross validation of the resulting partial least square (PLS)
models.
Network representation
Molfile-encoded chemical structures were retrieved from the
PubChem database. A pair-wise similarity matrix of Tanimoto
similarity coefficients among all the structures was performed using
the online structural clustering tool hosted at the PubChem Web
Pharmacometabolomic Signature of Ataxia SCA1 Mouse
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site. The matrix was subsequently converted into a Cytoscape
simple interaction format (SIF) formatted network using an in-
house Javascript (script available upon request). Kyoto Encyclo-
pedia of Genes and Genomes (KEGG) reaction pair relationships
were downloaded from the KEGG ftp site and parsed for the main
reactant pairs information. Using MS Excel, a single-step reaction
network was constructed for the identified metabolites and saved
as a SIF-formatted network. Both networks were imported into
Cytoscape [21] and merged using the ‘merge network’ plug-in.
Network graphs were visualized using an organic layout. Results of
differential ANOVA statistics and relative abundance changes
were mapped onto the node size (for magnitude of change), node
color (for up/downregulation) and ANOVA p-value (color
intensity), respectively.
Results
The overall study design has eight classes (2 genotypes62
treatments62 tissues) as shown in Table 1. Four hundred and
sixteen metabolites (416) were quantified, of which we identified
130 non-redundant identified compounds for analysis of impact on
metabolic networks. Structural identification of the 286 yet-
unidentified markers is a time-consuming and costly process and
thus beyond the scope of the work presented here. Raw data are
downloadable at http://fiehnlab.ucdavis.edu:8080/m1/
main_public.jsp [22–24] and attached as processed result files
with quantification ions, full mass spectra, retention indices,
database identifiers, names and external database references.
Plasma and cerebellar metabolic signature for Sca1154Q/+
mice
We compared metabolic profiles of cerebellum and blood in
Sca1154Q/+ and wild-type mice. Figure 1A shows good separation
of the four groups (plasma wild-type, plasma Sca1154Q/+, cerebel-
lum wild-type and cerebellum Sca1154Q/+). The overall variance
was clearly dominated by the differences in metabolite levels
between plasma and cerebellar tissue, indicated by the contribu-
tion of vector 1 (48% of the overall metabolic variance).
Differences that separated the two genotypes in both organs
(vector 3 and 4) used only 5% of the overall metabolic variance,
while vector 2 (not shown) was related to within-group variance.
The clear separation of metabolic clusters in both blood plasma
and cerebellum demonstrated that the disease-causing mutation is
responsible for metabolic differences that underlie the disease
phenotype in a systemic manner and were not confined to the
brain. Using one-way ANOVA tests for each comparison, 41
metabolites were found to be differentially regulated at p,0.05
between wild-type and Sca1154Q/+ mice in cerebellum, out of
which 18 were structurally identified using authentic standards.
We next set out to define the metabolic changes induced by
polyglutamine (polyQ) expansion in Sca1154Q/+ mice in plasma and
cerebellum. Table 2 shows all compounds found in plasma or
cerebellum at p,0.05 with the magnitude of difference in
metabolite levels, and shows the ratios of metabolites in
Sca1154Q/+/wild-type that differ between these two groups. A wide
range of metabolites were down-regulated in Sca1154Q/+ mice and
few were up-regulated. Metabolites that changed in the cerebellum
included intermediates in glucose, lipid, tricarboxylic acid (TCA)
cycle and purine metabolism, as well as a number of amino acids
including cysteine, beta-alanine and serine. The plasma of
Sca1154Q/+ mice showed higher levels of tryptophan and threonic
Table 1. Overall study design with the number of tested
animals.
Test Group Plasma Cerebellum
Wild-Type Sca1154Q/+ Wild-Type Sca1154Q/+
Control 11 16 10 16
Lithium treated 12 18 11 18
doi:10.1371/journal.pone.0070610.t001
Figure 1. Supervised multivariate Partial Least Square separa-
tion of metabolic phenotypes. A. Differences between plasma and
cerebellum (vector v1) and between SCA1 and wild-type under control
conditions (separated by vectors v3 and v4). B. Differences between
Lithium treated and control conditions in cerebellum (vector v1) and
between SCA1 and wild-type (separated by vectors v2 and v3).
Abbreviations: Cereb, Cerebellum; Ctrl, Control; Li, Lithium; WT, Wild-
type.
doi:10.1371/journal.pone.0070610.g001
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acid, and lower levels of phosphate and amino adipic acid
(Table 2). None of the identified metabolites were significantly
different in both organs, which points to specific impact of the
polyQ-expanded ATXN1 on both cerebellar biochemistry and
whole-body physiology. The difference in metabolite levels
between organs and the specific impact of the SCA1 gene on
plasma and cerebellum metabolism is visualized for nine selected
metabolites in Figure 2 (see Figure S1 for box-whisker plots of
other significant compounds from Table 2).
Comparison of central and peripheral biochemical
changes caused by lithium treatment
We investigated the effect of lithium treatment for both
genotypes, investigating individually for each organ. Eighty-five
metabolites significantly differed under lithium treatment (p,0.05,
one-way ANOVA) in at least one of the genotypes. Forty-two of
these compounds were structurally identified and are listed in
Table 3 with their respective p-values and magnitude of alteration.
In cerebellar tissue, lithium treatment caused the largest impact on
metabolic variation, affecting 42 of 44 significantly-affected
compounds. This led us to conclude that gender, weight and age
(other factors evaluated) of the mice were not relevant parameters
in this study.
We also found lithium treatment to be a significant parameter
for separating all cerebellar samples using PLS analysis (Figure 1B)
with vector 1 explaining 23% of the group-dependent variance.
Vectors 2 and 3 were not significant by themselves, but taken
together were able to classify the distinct effects of the wild-type
and Sca1154Q/+ mice under lithium treatment and control
conditions (explaining 29% of the group-dependent metabolic
variance). While even unsupervised multivariate analysis (prin-
cipal components analysis) could readily distinguish samples
between lithium-treated and untreated animals (graph not
shown), the within-group variance was too high to distinguish
the effects of Sca1154Q/+ without the classification power of
supervised PLS.
To pinpoint the significance level for each metabolite individ-
ually, we used univariate statistics to compare lithium-treated
versus control conditions in wild-type and in Sca1154Q/+ mice—
separately for both—in the cerebellum and plasma (see below).
Using multivariate ANOVA and using metabolites as dependent
variables and study parameters as covariates (lithium, genotype,
sex, age and weight), we found only 20 metabolites to be
significantly impacted by at least one parameter. Gender was
found to be significant for isoleucine, allo-inositol and aminoadipic
acid. As these metabolites were not significantly different per
lithium treatment, subsequent statistical analyses were performed
by combining data from both sexes. Using one-way ANOVA tests,
59 plasma metabolites were significantly differentially regulated
under lithium treatment when comparing both genotypes (wild-
Table 2. Genotype effect on metabolic profiles: Significantly different metabolites comparing wild-type versus Sca1154Q/+ mice
under control conditions.
Compounds Average level SCA1/Wild-Type p-value
Cerebellum Plasma Cerebellum Plasma
Glucose-6-phosphate 0.5 1.1 0.032 0.614
Cysteine 0.6 1.6 0.0004 0.057
Hypoxanthine 0.6 1.3 0.0004 0.291
Phosphoric acid 0.7 0.9 0.019 0.270
Beta-Mannosylglycerate 0.7 0.9 0.014 0.647
Phosphate 0.7 0.7 0.145 0.047
2-monopalmitin 0.7 1.0 0.005 0.790
Xanthine 0.7 1.1 0.007 0.873
Galactinol 0.7 2.0 0.003 0.361
Citric acid 0.8 1.1 0.030 0.378
Monopalmitin-1-glyceride 0.8 0.9 0.030 0.542
Hydroxycarbamate NIST 0.8 1.4 0.021 0.088
Inosine 0.8 1.2 0.003 0.241
Beta-alanine 0.8 0.6 0.012 0.136
2-aminoadipic acid 0.8 0.6 0.137 0.015
Serine 0.8 1.1 0.010 0.353
Glycerol-3-galactoside 0.8 1.5 0.014 0.372
Inositol allo- 0.8 0.8 0.043 0.225
Tryptophan 1.0 1.5 0.840 0.012
Idonic acid NIST 1.1 2.5 0.426 0.001
Threonic acid 1.2 2.6 0.209 0.001
Glycolic acid 1.2 0.9 0.028 0.414
Hexuronic acid 1.2 1.0 0.017 0.839
Notes: Bold indicates statistical significance. One-way analysis of variance performed separately for cerebellum and blood plasma (see Figure 2 and supplemental
Figure 1 for box-whisker plots). Abbreviation: NIST, National Institute of Standards and Technology.
doi:10.1371/journal.pone.0070610.t002
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type and Sca1154Q/+; ANOVA one-way p,0.05). Twenty-eight of
these compounds were annotated with identified structures
(Table 4; see Figure S2 for box-whisker plots of significant
compounds).
Plasma and cerebellar metabolic signature for lithium
treatment in wild-type mice
Lithium treatment in wild-type mice led to significant changes
in 33 metabolites in cerebellum and 14 in plasma. Malic acid,
fumaric acid, citric acid, methionine and pseudo uridine showed
changes in both tissues.
Lithium effects seen in wild-type mice (Table 3 and Figure 3
panel B, orange circles) were clustered to the purine biochemical
pathway (increased levels of xanthine, inosine, hypoxanthine),
sulphur and aromatic amino acids (increased levels of cysteine,
methionine, tryptophan, phenylalanine) and central energy
metabolism (increased concentrations for fructose, glucose, fruc-
tose-6-phosphate, glucose-6-phosphate and TCA metabolites
citrate, isocitrate, malate and fumarate with concomitant de-
creased levels of adenosine monophosphate [AMP]). There was
also a dramatically increased level of ascorbate which was
accompanied by reduction of threonate, and slightly increased
levels of unsaturated free fatty acids (elaidic acid, oleic acid and
linoleic acid).
While lithium treatment was the most significant study
parameter affecting metabolite levels in plasma, it had only
moderate effects on the identified metabolites (Figure 4). Similar to
what was found in cerebellar tissues, TCA metabolites were
increased with lithium treatment in wild-type mice (citric, aconitic,
isocitric, malic and fumaric acid), albeit at low abundance
differences.
Metabolic signature and therapeutic effect of lithium
treatment in Sca1154q/+ mice
Of 29 significantly altered metabolites in Sca1154Q/+ mouse
cerebellum after lithium treatment, nine were specific to Sca1154Q/+
mice. Moreover, lithium treatment affected 12 metabolites in
wild-type mice only. Those compounds that only responded to
lithium in one of the genotypes (Table 3 and Figure 3 Panel A,
green circles) indicate metabolic pathways that might be
disturbed by the action of the mutant Atxn1. For example,
ascorbic acid (Vitamin C) exhibited the overall highest fold
change in the cerebellum of wild-type mice (10-fold accumula-
tion, one-way ANOVA p= 0.002) but not Sca1154Q/+ mice. The
Figure 2. Effect of introducing the Sca1154Q/+ gene into the wild-type genetic background for plasma and cerebellum. Individual box-
whisker plots for selected significantly regulated metabolites. The whiskers encompass 1.5 of the interquartile range (IQR). Median value is indicated
with a line in the box. The confidence diamonds indicate average values when the two samples are statistically different (colored boxplots, red for
blood and grey for brain). Abbreviations: KI, SCA1 knock-in; WT, Wild-type.
doi:10.1371/journal.pone.0070610.g002
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increase of ascorbate in wild-type mice was accompanied by a
reduction of threonate (Figure 3 and Figure 5), which is an oxidative
catabolite of ascorbate (reaction pair KEGG RP01024). Interest-
ingly, the threonic acid/ascorbate reaction pair and dehydroascor-
bate were differentially regulated in the plasma of Sca1154Q/+ mice
but not wild-type mice, which was opposite to the finding in
cerebellum. In a different metabolite module, phytol and cholestan-
3-ol were also affected by lithium treatment in wild-type mice but
not in Sca1154Q/+ mice, albeit with a lower p-value (Table 3). Box-
whisker graphs for selected metabolites (Figure 5) highlight common
and specific responses to lithium treatment in the cerebellum (see
Figure S3 for box-whisker plots of other compounds from Table 3).
To assess the therapeutic effects of lithium, we looked at the
altered metabolites in Sca1154Q/+ mice that were corrected by
lithium treatment (Table 5). In the plasma of Sca1154Q/+ mice, the
levels of phosphate and 2-aminoadipic acid were down and the
levels of idonic acid NIST (National Institute of Standards and
Table 3. Effect of Lithium treatment on cerebellum metabolic
profile: Significantly different metabolites comparing Lithium
treatment versus control conditions.
Compound
Average Level
Li/control p-value
SCA1 Wild-Type SCA1 Wild-Type
Ascorbic acid 1.0 10.6 0.609 0.002
Glucose-6-phosphate 4.3 3.7 0.000 0.010
Fructose-6-phosphate 2.7 2.8 0.000 0.007
Elaidic acid 2.2 2.3 0.001 0.009
Glucose 1.8 2.3 0.017 0.021
Hypoxanthine 2.3 2.2 0.000 0.000
Fructose 1.8 1.6 0.118 0.001
Methionine 1.5 1.6 0.000 0.000
Maltose 2.9 1.6 0.000 0.019
Cysteine 1.8 1.6 0.000 0.000
Xanthine 1.8 1.5 0.000 0.003
Inositol-4-monophosphate 1.0 1.5 0.952 0.015
Citric acid 1.8 1.4 0.000 0.001
Tyrosine 1.2 1.4 0.041 0.023
Inosine 1.5 1.4 0.000 0.001
Fumaric acid 1.1 1.3 0.509 0.009
Oleic acid 1.2 1.3 0.001 0.008
Isocitric acid 1.5 1.3 0.000 0.004
Icosenoic acid 1.3 1.3 0.038 0.109
Linoleic acid 1.2 1.3 0.033 0.010
Tryptophan 1.3 1.3 0.015 0.039
Malic acid 1.2 1.2 0.027 0.008
Phenylalanine 1.2 1.2 0.020 0.019
Pseudo uridine 1.2 1.2 0.009 0.016
Pantothenic acid 1.3 1.2 0.006 0.087
Valine 1.2 1.2 0.134 0.017
Ornithine 1.3 1.2 0.009 0.132
Glycine 1.1 1.1 0.166 0.037
Monopalmitin-1-glyceride 1.3 1.1 0.008 0.300
Methionine sulfoxide 1.3 1.1 0.007 0.470
2-aminoadipic acid 1.3 1.0 0.043 0.799
Glycerol-alpha-phosphate 0.7 1.0 0.043 0.907
2-monopalmitin 1.4 1.0 0.003 0.698
Alloxanoic Acid NIST 0.7 0.9 0.001 0.324
Ethanolamine 0.9 0.8 0.475 0.032
Ribonic acid 0.9 0.8 0.400 0.030
Theonic acid 1.0 0.8 0.948 0.007
Nicotinamide 0.9 0.8 0.512 0.042
Glyceric acid 1.0 0.8 0.813 0.007
Phytol 1.1 0.6 0.664 0.002
Adenosine-5-monophosphate 0.5 0.5 0.001 0.011
Cholestan-3-ol 0.9 0.5 0.566 0.015
Note: Bold indicates statistical significance. One-way ANOVA performed
separately for wild-type and Sca1154Q/+ mice (see Figure 5 and supplemental
Figure 3 for box-whisker plots). Abbreviation: Li, Lithium.
doi:10.1371/journal.pone.0070610.t003
Table 4. Effect of Lithium treatment on blood plasma
metabolic profile: Significantly different metabolites
comparing Lithium treatment versus control conditions.
Compound
Average Level
Li/control p-value
SCA1 Wild-Type SCA1 Wild-Type
Icosenoic acid 2.0 2.1 0.042 0.287
Malic acid 1.8 1.8 0.000 0.001
2-aminoadipic acid 1.7 1.1 0.000 0.532
Fumaric acid 1.5 1.5 0.009 0.018
Glyceric acid 1.4 1.1 0.005 0.314
Phosphate 1.3 0.9 0.030 0.464
Dehydroascorbate 1.3 2.2 0.014 0.283
Ascorbic acid 1.3 1.1 0.021 0.407
Aconitic acid 1.3 1.7 0.115 0.015
Glycocyamine 1.3 3.7 0.014 0.254
Citric acid 1.3 1.5 0.002 0.000
Methionine 1.2 1.4 0.220 0.028
Isocitric acid 1.2 1.3 0.039 0.054
Stearic acid 1.2 1.6 0.092 0.002
Pseudo uridine 1.2 1.4 0.044 0.003
Indole-3-lactate 1.1 1.5 0.164 0.000
Palmitic acid 1.1 1.4 0.272 0.006
Indole-3-acetate 1.1 1.5 0.472 0.006
N-acetylaspartic acid 0.9 1.3 0.623 0.007
Sucrose 0.9 1.6 0.713 0.019
Aminomelonic acid 0.9 1.6 0.435 0.001
Hydroxycarbamate 0.9 1.5 0.338 0.016
Oxoproline 0.8 1.0 0.004 0.739
1-monostearin 0.8 0.9 0.023 0.738
Pyrazine 2,5-dihydroxy 0.7 1.1 0.025 0.544
Cysteine 0.6 1.1 0.006 0.663
Idonic acid NIST 0.5 1.2 0.000 0.671
Threonic acid 0.4 1.2 0.000 0.429
Note: Bold indicates statistical significance. One-way ANOVA performed
separately for wild-type and Sca1154Q/+ mice (see supplemental Figure 2 for box-
whisker plots). Abbreviation: Li, Lithium.
doi:10.1371/journal.pone.0070610.t004
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Technology), threonic acid and tryptophan were up compared to
the wild-type control animals. All of these, except for tryptophan,
were restored to their normal levels by lithium treatment.
Interestingly, none of these compounds were affected by lithium
treatment in wild-type mice. Therefore, these four metabolites
might be indicators of the disease suppression.
Similarly in the cerebellum, the levels of two closely-related
compounds, 2-monopalmitin and monopalmitin-1-glyceride, were
restored by lithium treatment in Sca1154Q/+ mice but were not
elevated in the wild-type lithium-treated animals. Among the
affected metabolites in the cerebellum of the Sca1154Q/+ mice, six
compounds were also affected by lithium treatment. The level of
these metabolites decreased in Sca1154Q/+ mouse cerebellum and
they were increased upon lithium treatment regardless of
genotype. In particular, when checking the ratio of hypoxanthine
and its corresponding nucleoside, inosine is similar in both the
wild-type and Sca1154Q/+ mice, respectively 0.5560.07 (average 6
standard deviation) and 0.4760.09. Upon lithium treatment, we
observed an increase in the hypoxanthine/inosine ratio by 56% to
0.8660.15 for the wild-type and 54% to 0.7260.13 for the
Sca1154Q/+ mice. Concurrent to that relative increase of hypoxan-
thine, the level of adenosine monophosphate is reduced by the
lithium treatment for both genotypes (Figure 5B).
Discussion
This study used a non-targeted metabolomics approach to map
global changes in metabolism centrally and peripherally in a
mouse model of ataxia before and after treatment with lithium.
Pure metabolic differences were noted in the plasma of Sca1154Q/+
mice compared to wild-type mice, which underscores the
importance of profiling relevant tissue in neurological disorders.
In plasma, threonate was significantly reduced in the Sca1154Q/+
mice, but neither ascorbate nor dehydroascorbate were signifi-
cantly different in both cerebellum and plasma. The amino acids
beta-alanine and cysteine were significantly decreased in cerebel-
lum, as were the purines xanthine, hypoxanthine and inosine.
Lithium neuroprotection mechanism is unclear, even if stimu-
lation of anti-apoptotic pathways has been shown, inhibiting the
activity of a serine/threonine kinase, the glycogen synthase kinase
3b (GSK3b) [25]. Lithium treatment also affects glucose transport,
enhances energy metabolism, particularly glucose metabolism
[26–28]. Corroborating with this notion our data show that
impaired central energy metabolism was restored to some degree
by lithium treatment.
The pathways affected by lithium—including the purine
biochemical pathway, sulphur-containing and aromatic amino
acids, central energy metabolism, unsaturated free fatty acids,
ascorbate and threonate—might all be related to the disease or to
benefit from treatment.
Threonate is a product of ascorbate oxidative cleavage (KEGG
reaction pair RP01024). The changes in ascorbate and threonate
only happened in lithium-treated wild-type but not Sca1154Q/+
mice. While we have not measured ascorbate levels in the diet,
both genotypes were fed the same Purina rodent chow with or
without the lithium supplement. Therefore, the observed differ-
ences cannot be related to how much ascorbate was provided. As
these differences were not seen in the plasma profiles of wild-type
mice, it is possible that lithium-treated wild-type mice respond by a
reduced catabolism of the antioxidant ascorbate into threonate in
the cerebellum (enzyme EC 1.13.11.13). This lithium response
appears to be suppressed in the Sca1154Q/+ mice. Ascorbate can
alternatively be oxidized to dehydroascorbate (enzyme EC
1.10.3.3) [29]. The Sca1154Q/+ mice showed differential levels of
threonate, ascorbate and dehydroascorbate in blood plasma, but
not in the cerebellum. The finding that the levels of ascorbic acid
and dehydroascorbate were much higher in blood plasma than in
cerebellum tissue suggests that lithium treatment might activate
ascorbate/dehydroascorbate uptake and is at least partly involved
in the ascorbate accumulation in the cerebellum. Targeted
experiments are required to further elucidate this complex
response.
Another pair of metabolites that respond differentially to lithium
treatment in cerebellar tissue between wild-type and Sca1154Q/+
mice is phytol and cholestan-3-ol (dihydrocholesterol). Cholestan-
3-ol was decreased in the cerebellum of lithium-treated wild-type
mice, but not in the cerebellum of lithium-treated Sca1154Q/+ mice.
Cholestan-3-ol binds to NCP2, which is associated with the
Nieman-Pick C2 neurodegenerative disease [30]. Deposits of
cholestan-3-ol in the brain define the hallmark of Cerebrotendi-
nous xanthomatosis, a rare genetic disease that is characterized by
progressive cerebellar ataxia [31–33]. The effect of lithium on
reducing levels of this cholesterol derivative in the cerebella of
wild-type but not Sca1154Q/+ mice indicates that the mechanisms
that control the levels of this metabolite are impaired in SCA1.
Significant accumulation of ascorbate in the cerebella of lithium-
treated wild-type but not SCA1 mice, and altered levels of phytol
(precursor for antioxidant Vitamin E biosynthesis) and cholestan-
3-ol (a similar compound exhibiting the same response to lithium
treatment) suggest that part of the lithium neuroprotective
properties could be mediated by reducing oxidative stress.
Inhibitory effects of lithium on components of inositol
phosphate metabolism have been suggested before [7]. Lithium
is an uncompetitive inhibitor of inositol phosphate metabolism and
the chronic lithium treatment leads to accumulation of inositol
monophosphates (InsP) [34]. Our result shows an increase of
inositol-4-monophosphate (Ins4P) upon lithium treatment, how-
ever this only happens in the wild-type but not in the mutant
animals.
The observed increase in aromatic and sulfur-containing
metabolites has been previously reported as an effect of lithium
treatment for the regulation of sulfur metabolism and cysteine-
string proteins in rat brain [35,36]. Sulfur amino acids have
already been associated with neurodegenerative disease [37].
Several of the pathways differentially regulated by the lithium
treatment in both wild-type and Sca1154Q/+ mice are well known to
be important for neurological diseases. The nucleotide salvage
pathway allows the cell to produce nucleotide monophosphates as
the de novo synthesis pathway is non-existent in the brain.
Measurement of AMP in the brain is dependent upon the sample
preparation as adenosine triphosphate can degrade to adenosine
diphosphate and AMP. The similar and statistically significant
responses observed in both genotypes indicate that the sample
Figure 3. Effect of lithium treatment on cerebellum metabolome. Metabolic network of wild-type and Sca1154Q/+ cerebellum phenotypes. A.
Wild-type mice. B. SCA1 knock-in mice. Red nodes: Increased metabolite levels under Lithium treatment; blue nodes: decreased levels. Node shades
indicate ANOVA significance levels, node size reflect differences in magnitude of regulation. Red lines: reactant pair relationships obtained from the
KEGG reaction pair database. Yellow solid lines: chemical similarity .0.5 Tanimoto score (Tanimoto scores range between 0 to 1, where 1 reflects
identical structures). Yellow broken lines: chemically closest structure at ,0.5 Tanimoto scores. Green circles group significant compounds that
changed only in the Wild-type genotype. Orange circles group significant compounds that changed in both genotypes.
doi:10.1371/journal.pone.0070610.g003
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Figure 4. Lithium treatment effect on blood plasma metabolome. Metabolic network of wild-type and Sca1154Q/+ plasma
phenotypes. A. Wild-type mice. B. SCA1 knock-in mice. Red nodes: Increased metabolite levels under Lithium treatment; blue nodes: decreased
levels. Node shades indicate ANOVA significance levels, node size reflect differences in magnitude of regulation. Red lines: reactant pair relationships
obtained from the KEGG reaction pair database. Yellow solid lines: chemical similarity .0.5 Tanimoto score (Tanimoto scores range between 0 to 1,
where 1 reflects identical structures). Yellow broken lines: chemically closest structure at ,0.5 Tanimoto scores.
doi:10.1371/journal.pone.0070610.g004
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preparation was proper and homogenous. Lithium treatment
causes a $50% increase in the efficiency of the purine salvage
pathway that converts inosine into hypoxanthine in both the
SCA1 and wild-type genotypes in a very similar way. The
differential regulation of the purines xanthine, hypoxanthine,
inosine and AMP under lithium treatment is consistent with the
hypothesis of a central role for this pathway in depression [38].
Xanthosine, the corresponding nucleoside of xanthine, has been
linked to stagger in sheep, thus associating purine to motor neuron
disease [39]. Further, recent studies have shown that ascorbate
levels act on the purine metabolism pathway, which suggests that
the effect of lithium on ascorbate and purine metabolites that was
observed in this study could be linked [40].
Neurodegenerative disorders have also been reported to exhibit
the loss of essential unsaturated fatty acids—such as linoleic acid—
in membranes [41], and linoleic acid was increased after lithium
treatment. Other neurodegenerative diseases have been associated
with inefficient glycolysis. We found that lithium treatment
increases the level of several molecules involved in glycolysis,
which is a critical pathway for energy production in the cell.
Lithium appears to boost levels of both glycolytic and TCA
intermediates, and may therefore alleviate the reported inefficien-
cy of glycolysis in neurological diseases [42–44].
None of these differential compounds appear directly associated
with any of a list of 194 differential transcripts, per a micro-array
analysis [45] performed on the same Sca1154Q/+ mouse model, and
similarly to the 19 differentials proteins of rat prefrontal cortex
after lithium treatment [46].
In conclusion, our findings corroborate previous reports that
lithium has multiple effects in neurological diseases. Our data
further reveal that lithium affects metabolic intermediates in the
cerebellum to a larger degree than in blood plasma. It also has a
controlling role in a variety of metabolic pathways, including
purine metabolism, oxidative stress reduction and energy produc-
tion.
Supporting Information
Figure S1 Effect of introducing the Sca1154Q/+ gene into
the wild-type genetic background for plasma and
cerebellum. This figure includes individual box-whisker plots
for other significantly regulated metabolites (i.e., compounds from
Table 2 not shown in Figure 2). The whiskers encompass 1.5 of the
interquartile range (IQR). Median value is indicated with a line in
the box. Abbreviations: Ctl, Control; KI, SCA1 knock-in; Li,
Lithium; WT, Wild-type.
(TIF)
Figure S2 Box-and-whisker plots: genotype-depen-
dent metabolites in plasma samples with significant
differences between lithium treatment and controls.
(p-value ,0.05; see Table 4). The whiskers encompass 1.5 of
the interquartile range (IQR). Median value is indicated with
a line in the box. Abbreviations: KI, SCA1 knock-in; WT,
Wild-type.
(TIF)
Figure S3 Box-and-whisker plots: genotype-dependent
metabolites in cerebellum samples with significant
differences between lithium treatment and controls. (p-
value ,0.05; see Table 3). The whiskers encompass 1.5 of the
interquartile range (IQR). Median value is indicated with a line in
the box. Abbreviations: Ctl, Control; KI, SCA1 knock-in; Li,
Lithium; WT, Wild-type.
(TIF)
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